Moderna, Inc. 8K

Moderna, Inc. reported Q2 2026 results showing a reduced net loss, reaffirmed its 2026 growth and expense outlook, announced new commercial agreements and regulatory milestones, disclosed a Phase 3 setback for its norovirus vaccine, and detailed leadership changes and upcoming pipeline catalysts.

On July 31, 2026, Moderna, Inc. reported its second quarter 2026 financial results, disclosing $145 million in revenue, a GAAP net loss of approximately $0.8 billion ($1.97 per share), and a cash and investments balance of $6.9 billion as of June 30, while tightening its 2026 financial framework by lowering expected cost of sales and R&D expenses, improving its projected year-end cash balance to $4.7–5.2 billion, and reiterating a target of up to 10% revenue growth for 2026. The company highlighted commercial progress, including new COVID and RSV vaccine supply and procurement agreements in Brazil and the EU and multiple international approvals for mRESVIA and mNEXSPIKE, as well as regulatory momentum for its seasonal influenza candidate mFLUSIVA and flu vaccine mRNA-1010 ahead of an August 5, 2026 PDUFA date. Moderna also provided pipeline updates, noting that its norovirus candidate mRNA-1403 failed to meet statistical criteria for early success at a Phase 3 interim analysis and will add an additional cohort, while late-stage oncology and rare disease programs, including intismeran (mRNA-4157) and mRNA-3927 for propionic acidemia, continued to advance toward key data readouts expected in 2026. In corporate governance updates, Moderna announced the appointment of Ester Banque as Chief Commercial Officer effective June 15, 2026, and Michael McDonnell, former Biogen CFO, to its Board of Directors effective July 8, 2026, and scheduled an Analyst Day for November 12, 2026.

Filing Facts

CIK

1682852

Ticker

MRNA

Form

8K

Source Type

fda

Accession

0001682852-26-000147

Alert Tier

7